Article Text

Download PDFPDF
Preoperative Prediction of Lymph Nodal Metastases in Endometrial Carcinoma: Is it Possible?
  1. Rami Fares, MSc, MRCS*,
  2. Sean Kehoe, MD, DCH, FRCOG and
  3. Nazem Shams, MD*
  1. *Department of Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt; and
  2. Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
  1. Address correspondence and reprint requests to Rami fares, MSc, MRCS, Mansoura University Faculty of Medicine, Mansoura, Egypt. E-mail:


Background Lymph node status is one of the most important prognostic factors in endometrial cancer and crucial for deciding adjuvant therapy.

Objective The aim of the study was to assess the different models used to predict lymphatic nodal disease.

Search Strategy A literature search was conducted to detect the relevant studies.

Inclusion Criteria Relevant papers comparing the preoperative modality with the final histopathological results including randomized clinical trials, case-control studies, and any publications with a minimum of 50 patients in the report.

Results Molecular-based predictors are still far from a practical application. Preoperative radiological scans (positron emission tomography, computed tomography, magnetic resonance imaging, and ultrasound) have shown the best predictor of lymphatic dissemination. However, there is currently no ideal model available, which can be used within standard clinical care.

Conclusions Surgical staging still remains the criterion standard in the determination of lymph node status in endometrial cancer.

  • Lymph nodes
  • Endometrial cancer
  • Computed scan
  • Magnetic resonance imaging
  • PET
  • Models
  • Molecular

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.